The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome

• Status: Completed
• Trial end date: 2017-12-30
• Target enrollment: 0
• Participant gender: All

Summary

This study will test the hypothesis that reducing the release of free fatty acids (FFA) from fat cells will restore insulin-mediated, endothelium-dependent vasodilation in people with the metabolic syndrome.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Brigham and Women's Hospital
• Treatments: Acipimox

Criteria

Inclusion Criteria:

• Adults with metabolic syndrome, defined as the presence of 3 of 5 components of the syndrome as defined by the National Cholesterol Education Program including:

• abdominal obesity

• elevated fasting blood sugar (110 mg/dL< glucose < 126 mg/dL)

• low HDL

• elevated fasting blood triglycerides (> 150 mg/dL)

• hypertension (BP > 140/90 mm HG)

• Normal cardiovascular examination

Exclusion Criteria:

• Diabetes mellitus

• Untreated hypercholesterolemia (LDL > 75th percentile for age)

• Cigarette smoking within 1 year

• Renal insufficiency (creatinine > 1.4 mg/dl)

• Blood dyscrasia

• Hepatic dysfunction (ALT > 2x normal)

• Evident coronary/peripheral atherosclerosis